Delta4 files four patent applications in FSGS and COVID-19
We are very pleased to announce that Delta4 has filed four patent applications for compounds and combinations of compounds in our drug discovery programs in FSGS and COVID-19. FSGS, or Focal Segmental Glomerulosclerosis, is a devastating renal disease with high and urgent medical need. We initiated our discovery program in this disease in Q4 2019 […]